Drug Profile
Davunetide intravenous
Alternative Names: AL-208; Davunetide IVLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Allon Therapeutics
- Class Antidementias; Eye disorder therapies; Neuropeptides; Neuroprotectants; Nootropics
- Mechanism of Action Microtubule-associated protein inhibitors; Microtubule-associated protein modulators; Neuropeptide stimulants; Tau protein inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Dementia; Diabetic neuropathies; Eye disorders; Mild cognitive impairment; Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dementia in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in Canada (IV)
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International